カテゴリー： LP Information, 世界, 医療/バイオ

メトホルミン塩酸塩徐放剤のグローバル市場予測2023-2029

◆英語タイトル：Global Metformin Hydrochloride Sustained-release Drug Market Growth 2023-2029
	◆商品コード：LP23DC05124 ◆発行会社（リサーチ会社）：LP Information ◆発行日：2023年11月 ◆ページ数：117 ◆レポート形式：英語 / PDF ◆納品方法：Eメール（受注後2-3営業日） ◆調査対象地域：グローバル、日本、アメリカ、ヨーロッパ、アジア、中国など ◆産業分野：医薬品＆医療

◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD3,660 ⇒換算￥556,320	見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）	USD5,490 ⇒換算￥834,480	見積依頼/購入/質問フォーム
Corporate User（閲覧人数制限なし）	USD7,320 ⇒換算￥1,112,640	見積依頼/購入/質問フォーム

★LP Informationに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

LP Informationの最新刊調査レポート「メトホルミン塩酸塩徐放剤のグローバル市場」は、過去の販売実績から2022年の世界のメトホルミン塩酸塩徐放剤の総販売量を検討し、2023年から2029年の予測されるメトホルミン塩酸塩徐放剤の販売量を地域別・市場分野別に包括的に分析しています。本調査レポートでは、地域別、市場分野別、サブセクター別のメトホルミン塩酸塩徐放剤の市場規模を掲載し、XXX百万米ドル規模の世界のメトホルミン塩酸塩徐放剤市場の詳細な分析を提供します。本インサイトレポートは、世界のメトホルミン塩酸塩徐放剤業界を包括的に分析し、製品セグメント、企業情報、売上、市場シェア、最新動向、M&A活動に関する主要トレンドを明らかにしています。
また、本レポートでは、加速する世界のメトホルミン塩酸塩徐放剤市場における各社の独自のポジションをより深く理解するために、メトホルミン塩酸塩徐放剤製品ポートフォリオ、能力、市場参入戦略、市場でのポジション、海外展開に焦点を当て、主要なグローバル企業の戦略を分析しています。

世界のメトホルミン塩酸塩徐放剤市場規模は、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに成長すると予測され、2023年から2029年までの年平均成長率は000%と予測されます。メトホルミン塩酸塩徐放剤の米国市場は、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加し、2023年から2029年までのCAGRは000％と予測されています。メトホルミン塩酸塩徐放剤の中国市場は、2023年から2029年までの年平均000％成長率で、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加すると推定されます。メトホルミン塩酸塩徐放剤のヨーロッパ市場は、2023年から2029年にかけて年平均000％成長率で、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加すると推定されています。

メトホルミン塩酸塩徐放剤の世界主要メーカーとしては、Merck、 Viatris、 Apotex、 Teva Pharmaceuticals、 Sun Pharmaceutical Industries、 Dr. Reddy's Laboratories、 CSPC、 Jingfeng Pharmaceutical Group、 Topfond Pharmaceutical、 SinocorpPharma、 CTTQ、 Shanghai Pharmaceuticals、 Tianan Pharmaceutical、 Qingdao Huanghai Pharmaceutical、 Chongqing Conquer Pharmaceutical、 Jiangsu Deyuan Pharmaceutical、 Beijing Shengyong Pharmaceuticalなどを掲載しており、売上の面では、世界の2大企業が2022年にほぼ000％のシェアを占めています。

本レポートでは、製品タイプ、用途、主要メーカー、主要地域、国別のメトホルミン塩酸塩徐放剤市場の包括的な概要、市場シェア、成長機会などの情報を提供しています。

【市場セグメンテーション】

この調査ではメトホルミン塩酸塩徐放剤市場をセグメンテーションし、種類別 (錠剤、カプセル)、用途別 (病院、診療所、その他)、および地域別 (アジア太平洋、南北アメリカ、ヨーロッパ、および中東・アフリカ) の市場規模を予測しています。

・種類別区分：錠剤、カプセル

・用途別区分：病院、診療所、その他

・地域別区分
南北アメリカ（米国、カナダ、メキシコ、ブラジル）
アジア太平洋（中国、日本、韓国、東南アジア、インド、オーストラリア）
ヨーロッパ（ドイツ、フランス、イギリス、イタリア、ロシア）
中東・アフリカ（エジプト、南アフリカ、イスラエル、トルコ、GCC諸国）

【本レポートで扱う主な質問】

・世界のメトホルミン塩酸塩徐放剤市場の10年間の市場状況・展望は？
・世界および地域別に見たメトホルミン塩酸塩徐放剤市場成長の要因は何か？
・メトホルミン塩酸塩徐放剤の市場機会はエンドマーケットの規模によってどのように変化するのか？
・メトホルミン塩酸塩徐放剤のタイプ別、用途別の内訳は？
・新型コロナウイルスとロシア・ウクライナ戦争の影響は？

********* 目次 *********

レポートの範囲
・市場の紹介
・分析対象期間
・調査の目的
・調査手法
・調査プロセスおよびデータソース
・経済指標
・通貨

エグゼクティブサマリー
・世界市場の概要：メトホルミン塩酸塩徐放剤の年間販売量2018-2029、地域別現状・将来分析
・メトホルミン塩酸塩徐放剤の種類別セグメント：錠剤、カプセル
・メトホルミン塩酸塩徐放剤の種類別販売量：2018-2023年の販売量、売上、市場シェア、販売価格
・メトホルミン塩酸塩徐放剤の用途別セグメント：病院、診療所、その他
・メトホルミン塩酸塩徐放剤の用途別販売量：2018-2023年の販売量、売上、市場シェア、販売価格

企業別世界のメトホルミン塩酸塩徐放剤市場
・企業別のグローバルメトホルミン塩酸塩徐放剤市場データ：2018-2023年の年間販売量、市場シェア
・企業別のメトホルミン塩酸塩徐放剤の年間売上：2018-2023年の売上、市場シェア
・企業別のメトホルミン塩酸塩徐放剤販売価格
・主要企業のメトホルミン塩酸塩徐放剤生産地域、販売地域、製品タイプ
・市場集中度分析
・新製品および潜在的な参加者
・合併と買収、拡大

メトホルミン塩酸塩徐放剤の地域別レビュー
・地域別のメトホルミン塩酸塩徐放剤市場規模2018-2023：年間販売量、売上
・主要国別のメトホルミン塩酸塩徐放剤市場規模2018-2023：年間販売量、売上
・南北アメリカのメトホルミン塩酸塩徐放剤販売の成長
・アジア太平洋のメトホルミン塩酸塩徐放剤販売の成長
・ヨーロッパのメトホルミン塩酸塩徐放剤販売の成長
・中東・アフリカのメトホルミン塩酸塩徐放剤販売の成長

南北アメリカ市場
・南北アメリカの国別のメトホルミン塩酸塩徐放剤販売量、売上（2018-2023）
・南北アメリカのメトホルミン塩酸塩徐放剤の種類別販売量
・南北アメリカのメトホルミン塩酸塩徐放剤の用途別販売量
・米国市場
・カナダ市場
・メキシコ市場
・ブラジル市場

アジア太平洋市場
・アジア太平洋の国別のメトホルミン塩酸塩徐放剤販売量、売上（2018-2023）
・アジア太平洋のメトホルミン塩酸塩徐放剤の種類別販売量
・アジア太平洋のメトホルミン塩酸塩徐放剤の用途別販売量
・中国市場
・日本市場
・韓国市場
・東南アジア市場
・インド市場
・オーストラリア市場
・台湾市場

ヨーロッパ市場
・ヨーロッパの国別のメトホルミン塩酸塩徐放剤販売量、売上（2018-2023）
・ヨーロッパのメトホルミン塩酸塩徐放剤の種類別販売量
・ヨーロッパのメトホルミン塩酸塩徐放剤の用途別販売量
・ドイツ市場
・フランス市場
・イギリス市場
・イタリア市場
・ロシア市場

中東・アフリカ市場
・中東・アフリカの国別のメトホルミン塩酸塩徐放剤販売量、売上（2018-2023）
・中東・アフリカのメトホルミン塩酸塩徐放剤の種類別販売量
・中東・アフリカのメトホルミン塩酸塩徐放剤の用途別販売量
・エジプト市場
・南アフリカ市場
・イスラエル市場
・トルコ市場
・GCC諸国市場

市場の成長要因、課題、動向
・市場の成長要因および成長機会分析
・市場の課題およびリスク
・市場動向

製造コスト構造分析
・原材料とサプライヤー
・メトホルミン塩酸塩徐放剤の製造コスト構造分析
・メトホルミン塩酸塩徐放剤の製造プロセス分析
・メトホルミン塩酸塩徐放剤の産業チェーン構造

マーケティング、販売業者および顧客
・販売チャンネル：直接販売チャンネル、間接販売チャンネル
・メトホルミン塩酸塩徐放剤の主要なグローバル販売業者
・メトホルミン塩酸塩徐放剤の主要なグローバル顧客

地域別のメトホルミン塩酸塩徐放剤市場予測レビュー
・地域別のメトホルミン塩酸塩徐放剤市場規模予測（2024-2029）
・南北アメリカの国別予測
・アジア太平洋の国別予測
・ヨーロッパの国別予測
・メトホルミン塩酸塩徐放剤の種類別市場規模予測
・メトホルミン塩酸塩徐放剤の用途別市場規模予測

主要企業分析
Merck、 Viatris、 Apotex、 Teva Pharmaceuticals、 Sun Pharmaceutical Industries、 Dr. Reddy's Laboratories、 CSPC、 Jingfeng Pharmaceutical Group、 Topfond Pharmaceutical、 SinocorpPharma、 CTTQ、 Shanghai Pharmaceuticals、 Tianan Pharmaceutical、 Qingdao Huanghai Pharmaceutical、 Chongqing Conquer Pharmaceutical、 Jiangsu Deyuan Pharmaceutical、 Beijing Shengyong Pharmaceutical
・企業情報
・メトホルミン塩酸塩徐放剤製品
・メトホルミン塩酸塩徐放剤販売量、売上、価格、粗利益（2018-2023）
・主要ビジネス概要
・最新動向

調査結果および結論

The global Metformin Hydrochloride Sustained-release Drug market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Metformin Hydrochloride Sustained-release Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Metformin Hydrochloride Sustained-release Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Metformin Hydrochloride Sustained-release Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Metformin Hydrochloride Sustained-release Drug players cover Merck, Viatris, Apotex, Teva Pharmaceuticals, Sun Pharmaceutical Industries, Dr. Reddy’s Laboratories, CSPC, Jingfeng Pharmaceutical Group and Topfond Pharmaceutical, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
Metformin hydrochloride sustained-release drug is a medication used to treat type 2 diabetes. It is a long-acting form of metformin, which helps to lower blood sugar levels by decreasing the amount of glucose produced by the liver and increasing the body’s sensitivity to insulin.
LPI (LP Information)’ newest research report, the “Metformin Hydrochloride Sustained-release Drug Industry Forecast” looks at past sales and reviews total world Metformin Hydrochloride Sustained-release Drug sales in 2022, providing a comprehensive analysis by region and market sector of projected Metformin Hydrochloride Sustained-release Drug sales for 2023 through 2029. With Metformin Hydrochloride Sustained-release Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Metformin Hydrochloride Sustained-release Drug industry.
This Insight Report provides a comprehensive analysis of the global Metformin Hydrochloride Sustained-release Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Metformin Hydrochloride Sustained-release Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Metformin Hydrochloride Sustained-release Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Metformin Hydrochloride Sustained-release Drug and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Metformin Hydrochloride Sustained-release Drug.
This report presents a comprehensive overview, market shares, and growth opportunities of Metformin Hydrochloride Sustained-release Drug market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Tablet
Capsule
Segmentation by application
Hospital
Clinic
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company’s coverage, product portfolio, its market penetration.
Merck
Viatris
Apotex
Teva Pharmaceuticals
Sun Pharmaceutical Industries
Dr. Reddy’s Laboratories
CSPC
Jingfeng Pharmaceutical Group
Topfond Pharmaceutical
SinocorpPharma
CTTQ
Shanghai Pharmaceuticals
Tianan Pharmaceutical
Qingdao Huanghai Pharmaceutical
Chongqing Conquer Pharmaceutical
Jiangsu Deyuan Pharmaceutical
Beijing Shengyong Pharmaceutical
Key Questions Addressed in this Report
What is the 10-year outlook for the global Metformin Hydrochloride Sustained-release Drug market?
What factors are driving Metformin Hydrochloride Sustained-release Drug market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Metformin Hydrochloride Sustained-release Drug market opportunities vary by end market size?
How does Metformin Hydrochloride Sustained-release Drug break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?

❖ レポートの目次 ❖

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Metformin Hydrochloride Sustained-release Drug Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Metformin Hydrochloride Sustained-release Drug by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Metformin Hydrochloride Sustained-release Drug by Country/Region, 2018, 2022 & 2029
2.2 Metformin Hydrochloride Sustained-release Drug Segment by Type
2.2.1 Tablet
2.2.2 Capsule
2.3 Metformin Hydrochloride Sustained-release Drug Sales by Type
2.3.1 Global Metformin Hydrochloride Sustained-release Drug Sales Market Share by Type (2018-2023)
2.3.2 Global Metformin Hydrochloride Sustained-release Drug Revenue and Market Share by Type (2018-2023)
2.3.3 Global Metformin Hydrochloride Sustained-release Drug Sale Price by Type (2018-2023)
2.4 Metformin Hydrochloride Sustained-release Drug Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Other
2.5 Metformin Hydrochloride Sustained-release Drug Sales by Application
2.5.1 Global Metformin Hydrochloride Sustained-release Drug Sale Market Share by Application (2018-2023)
2.5.2 Global Metformin Hydrochloride Sustained-release Drug Revenue and Market Share by Application (2018-2023)
2.5.3 Global Metformin Hydrochloride Sustained-release Drug Sale Price by Application (2018-2023)
3 Global Metformin Hydrochloride Sustained-release Drug by Company
3.1 Global Metformin Hydrochloride Sustained-release Drug Breakdown Data by Company
3.1.1 Global Metformin Hydrochloride Sustained-release Drug Annual Sales by Company (2018-2023)
3.1.2 Global Metformin Hydrochloride Sustained-release Drug Sales Market Share by Company (2018-2023)
3.2 Global Metformin Hydrochloride Sustained-release Drug Annual Revenue by Company (2018-2023)
3.2.1 Global Metformin Hydrochloride Sustained-release Drug Revenue by Company (2018-2023)
3.2.2 Global Metformin Hydrochloride Sustained-release Drug Revenue Market Share by Company (2018-2023)
3.3 Global Metformin Hydrochloride Sustained-release Drug Sale Price by Company
3.4 Key Manufacturers Metformin Hydrochloride Sustained-release Drug Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Metformin Hydrochloride Sustained-release Drug Product Location Distribution
3.4.2 Players Metformin Hydrochloride Sustained-release Drug Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Metformin Hydrochloride Sustained-release Drug by Geographic Region
4.1 World Historic Metformin Hydrochloride Sustained-release Drug Market Size by Geographic Region (2018-2023)
4.1.1 Global Metformin Hydrochloride Sustained-release Drug Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Metformin Hydrochloride Sustained-release Drug Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Metformin Hydrochloride Sustained-release Drug Market Size by Country/Region (2018-2023)
4.2.1 Global Metformin Hydrochloride Sustained-release Drug Annual Sales by Country/Region (2018-2023)
4.2.2 Global Metformin Hydrochloride Sustained-release Drug Annual Revenue by Country/Region (2018-2023)
4.3 Americas Metformin Hydrochloride Sustained-release Drug Sales Growth
4.4 APAC Metformin Hydrochloride Sustained-release Drug Sales Growth
4.5 Europe Metformin Hydrochloride Sustained-release Drug Sales Growth
4.6 Middle East & Africa Metformin Hydrochloride Sustained-release Drug Sales Growth
5 Americas
5.1 Americas Metformin Hydrochloride Sustained-release Drug Sales by Country
5.1.1 Americas Metformin Hydrochloride Sustained-release Drug Sales by Country (2018-2023)
5.1.2 Americas Metformin Hydrochloride Sustained-release Drug Revenue by Country (2018-2023)
5.2 Americas Metformin Hydrochloride Sustained-release Drug Sales by Type
5.3 Americas Metformin Hydrochloride Sustained-release Drug Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Metformin Hydrochloride Sustained-release Drug Sales by Region
6.1.1 APAC Metformin Hydrochloride Sustained-release Drug Sales by Region (2018-2023)
6.1.2 APAC Metformin Hydrochloride Sustained-release Drug Revenue by Region (2018-2023)
6.2 APAC Metformin Hydrochloride Sustained-release Drug Sales by Type
6.3 APAC Metformin Hydrochloride Sustained-release Drug Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Metformin Hydrochloride Sustained-release Drug by Country
7.1.1 Europe Metformin Hydrochloride Sustained-release Drug Sales by Country (2018-2023)
7.1.2 Europe Metformin Hydrochloride Sustained-release Drug Revenue by Country (2018-2023)
7.2 Europe Metformin Hydrochloride Sustained-release Drug Sales by Type
7.3 Europe Metformin Hydrochloride Sustained-release Drug Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Metformin Hydrochloride Sustained-release Drug by Country
8.1.1 Middle East & Africa Metformin Hydrochloride Sustained-release Drug Sales by Country (2018-2023)
8.1.2 Middle East & Africa Metformin Hydrochloride Sustained-release Drug Revenue by Country (2018-2023)
8.2 Middle East & Africa Metformin Hydrochloride Sustained-release Drug Sales by Type
8.3 Middle East & Africa Metformin Hydrochloride Sustained-release Drug Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Metformin Hydrochloride Sustained-release Drug
10.3 Manufacturing Process Analysis of Metformin Hydrochloride Sustained-release Drug
10.4 Industry Chain Structure of Metformin Hydrochloride Sustained-release Drug
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Metformin Hydrochloride Sustained-release Drug Distributors
11.3 Metformin Hydrochloride Sustained-release Drug Customer
12 World Forecast Review for Metformin Hydrochloride Sustained-release Drug by Geographic Region
12.1 Global Metformin Hydrochloride Sustained-release Drug Market Size Forecast by Region
12.1.1 Global Metformin Hydrochloride Sustained-release Drug Forecast by Region (2024-2029)
12.1.2 Global Metformin Hydrochloride Sustained-release Drug Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Metformin Hydrochloride Sustained-release Drug Forecast by Type
12.7 Global Metformin Hydrochloride Sustained-release Drug Forecast by Application
13 Key Players Analysis
13.1 Merck
13.1.1 Merck Company Information
13.1.2 Merck Metformin Hydrochloride Sustained-release Drug Product Portfolios and Specifications
13.1.3 Merck Metformin Hydrochloride Sustained-release Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Merck Main Business Overview
13.1.5 Merck Latest Developments
13.2 Viatris
13.2.1 Viatris Company Information
13.2.2 Viatris Metformin Hydrochloride Sustained-release Drug Product Portfolios and Specifications
13.2.3 Viatris Metformin Hydrochloride Sustained-release Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Viatris Main Business Overview
13.2.5 Viatris Latest Developments
13.3 Apotex
13.3.1 Apotex Company Information
13.3.2 Apotex Metformin Hydrochloride Sustained-release Drug Product Portfolios and Specifications
13.3.3 Apotex Metformin Hydrochloride Sustained-release Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Apotex Main Business Overview
13.3.5 Apotex Latest Developments
13.4 Teva Pharmaceuticals
13.4.1 Teva Pharmaceuticals Company Information
13.4.2 Teva Pharmaceuticals Metformin Hydrochloride Sustained-release Drug Product Portfolios and Specifications
13.4.3 Teva Pharmaceuticals Metformin Hydrochloride Sustained-release Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Teva Pharmaceuticals Main Business Overview
13.4.5 Teva Pharmaceuticals Latest Developments
13.5 Sun Pharmaceutical Industries
13.5.1 Sun Pharmaceutical Industries Company Information
13.5.2 Sun Pharmaceutical Industries Metformin Hydrochloride Sustained-release Drug Product Portfolios and Specifications
13.5.3 Sun Pharmaceutical Industries Metformin Hydrochloride Sustained-release Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Sun Pharmaceutical Industries Main Business Overview
13.5.5 Sun Pharmaceutical Industries Latest Developments
13.6 Dr. Reddy’s Laboratories
13.6.1 Dr. Reddy’s Laboratories Company Information
13.6.2 Dr. Reddy’s Laboratories Metformin Hydrochloride Sustained-release Drug Product Portfolios and Specifications
13.6.3 Dr. Reddy’s Laboratories Metformin Hydrochloride Sustained-release Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Dr. Reddy’s Laboratories Main Business Overview
13.6.5 Dr. Reddy’s Laboratories Latest Developments
13.7 CSPC
13.7.1 CSPC Company Information
13.7.2 CSPC Metformin Hydrochloride Sustained-release Drug Product Portfolios and Specifications
13.7.3 CSPC Metformin Hydrochloride Sustained-release Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 CSPC Main Business Overview
13.7.5 CSPC Latest Developments
13.8 Jingfeng Pharmaceutical Group
13.8.1 Jingfeng Pharmaceutical Group Company Information
13.8.2 Jingfeng Pharmaceutical Group Metformin Hydrochloride Sustained-release Drug Product Portfolios and Specifications
13.8.3 Jingfeng Pharmaceutical Group Metformin Hydrochloride Sustained-release Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Jingfeng Pharmaceutical Group Main Business Overview
13.8.5 Jingfeng Pharmaceutical Group Latest Developments
13.9 Topfond Pharmaceutical
13.9.1 Topfond Pharmaceutical Company Information
13.9.2 Topfond Pharmaceutical Metformin Hydrochloride Sustained-release Drug Product Portfolios and Specifications
13.9.3 Topfond Pharmaceutical Metformin Hydrochloride Sustained-release Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Topfond Pharmaceutical Main Business Overview
13.9.5 Topfond Pharmaceutical Latest Developments
13.10 SinocorpPharma
13.10.1 SinocorpPharma Company Information
13.10.2 SinocorpPharma Metformin Hydrochloride Sustained-release Drug Product Portfolios and Specifications
13.10.3 SinocorpPharma Metformin Hydrochloride Sustained-release Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 SinocorpPharma Main Business Overview
13.10.5 SinocorpPharma Latest Developments
13.11 CTTQ
13.11.1 CTTQ Company Information
13.11.2 CTTQ Metformin Hydrochloride Sustained-release Drug Product Portfolios and Specifications
13.11.3 CTTQ Metformin Hydrochloride Sustained-release Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 CTTQ Main Business Overview
13.11.5 CTTQ Latest Developments
13.12 Shanghai Pharmaceuticals
13.12.1 Shanghai Pharmaceuticals Company Information
13.12.2 Shanghai Pharmaceuticals Metformin Hydrochloride Sustained-release Drug Product Portfolios and Specifications
13.12.3 Shanghai Pharmaceuticals Metformin Hydrochloride Sustained-release Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Shanghai Pharmaceuticals Main Business Overview
13.12.5 Shanghai Pharmaceuticals Latest Developments
13.13 Tianan Pharmaceutical
13.13.1 Tianan Pharmaceutical Company Information
13.13.2 Tianan Pharmaceutical Metformin Hydrochloride Sustained-release Drug Product Portfolios and Specifications
13.13.3 Tianan Pharmaceutical Metformin Hydrochloride Sustained-release Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 Tianan Pharmaceutical Main Business Overview
13.13.5 Tianan Pharmaceutical Latest Developments
13.14 Qingdao Huanghai Pharmaceutical
13.14.1 Qingdao Huanghai Pharmaceutical Company Information
13.14.2 Qingdao Huanghai Pharmaceutical Metformin Hydrochloride Sustained-release Drug Product Portfolios and Specifications
13.14.3 Qingdao Huanghai Pharmaceutical Metformin Hydrochloride Sustained-release Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 Qingdao Huanghai Pharmaceutical Main Business Overview
13.14.5 Qingdao Huanghai Pharmaceutical Latest Developments
13.15 Chongqing Conquer Pharmaceutical
13.15.1 Chongqing Conquer Pharmaceutical Company Information
13.15.2 Chongqing Conquer Pharmaceutical Metformin Hydrochloride Sustained-release Drug Product Portfolios and Specifications
13.15.3 Chongqing Conquer Pharmaceutical Metformin Hydrochloride Sustained-release Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.15.4 Chongqing Conquer Pharmaceutical Main Business Overview
13.15.5 Chongqing Conquer Pharmaceutical Latest Developments
13.16 Jiangsu Deyuan Pharmaceutical
13.16.1 Jiangsu Deyuan Pharmaceutical Company Information
13.16.2 Jiangsu Deyuan Pharmaceutical Metformin Hydrochloride Sustained-release Drug Product Portfolios and Specifications
13.16.3 Jiangsu Deyuan Pharmaceutical Metformin Hydrochloride Sustained-release Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.16.4 Jiangsu Deyuan Pharmaceutical Main Business Overview
13.16.5 Jiangsu Deyuan Pharmaceutical Latest Developments
13.17 Beijing Shengyong Pharmaceutical
13.17.1 Beijing Shengyong Pharmaceutical Company Information
13.17.2 Beijing Shengyong Pharmaceutical Metformin Hydrochloride Sustained-release Drug Product Portfolios and Specifications
13.17.3 Beijing Shengyong Pharmaceutical Metformin Hydrochloride Sustained-release Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.17.4 Beijing Shengyong Pharmaceutical Main Business Overview
13.17.5 Beijing Shengyong Pharmaceutical Latest Developments
14 Research Findings and Conclusion

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ メトホルミン塩酸塩徐放剤のグローバル市場予測2023-2029(Global Metformin Hydrochloride Sustained-release Drug Market Growth 2023-2029)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

メトホルミン塩酸塩徐放剤のグローバル市場予測2023-2029

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp